<DOC>
	<DOCNO>NCT01347242</DOCNO>
	<brief_summary>This phase I/II study evaluate safety efficacy Hematopoietic Stem Cell genetherapy Wiskott-Aldrich Syndrome .</brief_summary>
	<brief_title>Gene Therapy Wiskott-Aldrich Syndrome ( WAS )</brief_title>
	<detailed_description>This clinical trial ex vivo gene therapy trial . The investigational product correspond autologous CD34+ cell transduce lentiviral vector harbor human WASP gene .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Wiskott-Aldrich Syndrome</mesh_term>
	<criteria>male age severe WAS ( clinical score 35 ) absence WAS protein peripheral blood mononuclear cell determine Western blot flow cytometry molecular confirmation WAS gene DNA sequence lack HLAgenotypically identical bone marrow 10/10 antigen HLAmatched unrelated donor cord blood 3 month search parental , guardian , patient sign informed consent/assent willing return followup patient receive previous allogenic hematopoietic stem cell transplant : fail allogenic hematopoietic stem cell transplant contraindication repeat transplantation patient HLAgenotypically identical bone marrow patient 10/10 antigen HLAmatched unrelated donor cord blood contraindication leukapheresis contraindication bone marrow harvest contraindication administration condition medication HIV positive patient</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Wiskott-Aldrich Syndrome</keyword>
	<keyword>Primary immune deficiency</keyword>
	<keyword>ex vivo gene therapy</keyword>
	<keyword>hematopoietic stem cell</keyword>
</DOC>